Gastroparesis — Causes, Diagnosis and Diet

Gastroparesis is defined as a chronic motility disorder where there is delayed emptying of the stomach without an apparent mechanical obstruction. Usually, both solids and liquids are affected. Gastroparesis is usually of undetermined causes, but can also be linked to previous abdominal surgeries or diabetes mellitus. Symptoms include nausea, vomiting, and early satiety. Once diagnosed, the patient is instructed to follow a diet that has more liquid, promotility agents could be prescribed and antiemetics are used for symptomatic relief.

General Information About Gastroparesis

Patients with gastroparesis have *delayed stomach emptying* of food without evidence of mechanical obstruction. *Gastric motility* is controlled by the *vagus nerve*, smooth muscle cells, and enteric neurons.

To understand the possible etiologies of gastroparesis, you should know that one of the ABOVE three control levels has to be impaired in order for the patient to develop the disease.

While the majority of the cases do not have a clear etiology, *diabetes* and *abdominal surgeries* have been both linked to the development of gastroparesis.

Symptoms of gastroparesis are non-specific, which makes the diagnosis even more challenging. They include *abdominal pain*, *early satiety*, *bloating*, *vomiting* and *nausea*. If left untreated, severe gastroparesis can cause *esophagitis*, *bezoar formation* or *Mallory-Weiss tears* due to repeated vomiting.
Epidemiology of Gastroparesis

Due to the non-specificity of the symptoms, it is difficult to know exactly the prevalence of gastroparesis in the USA. Some studies put the incidence of gastroparesis at 2.5 per 100,000 for men and 9.6 per 100,000 for women.

These numbers show that gastroparesis is more common in women which is in agreement with another study of gastroparesis patients where they reported that 84% of the patients were women. Interestingly, healthy women usually have a delayed emptying rate compared to men which could, in theory, make them more predisposed to gastroparesis.

In another approach to study the prevalence of gastroparesis, few studies tried to focus on specific populations that are known to have an increased risk of gastrointestinal symptoms.

Diabetes, in particular, has been found to be strongly linked to gastrointestinal symptoms in general and gastroparesis in particular. Current studies show that diabetics if investigated in tertiary specialized centers, are very likely to have delayed gastric emptying. For instance, up to 65% of diabetic patients were reported to have gastroparesis in one study.

Gastroparesis related hospitalizations have doubled in the last decade because of the increasing prevalence of diabetes and gastroesophageal reflux disease-related surgeries. Additionally, the total costs related to these hospitalizations are rated as the highest if compared to hospitalizations for gastric ulcers, gastritis or gastroesophageal reflux disease.
Etiologies of Gastroparesis

The most commonly encountered etiologies of gastroparesis are idiopathic, followed by diabetic and finally postgastric surgery related. Less common etiologies include Parkinson’s disease and collagen disorders.

Idiopathic gastroparesis

Idiopathic gastroparesis is a term used when the exact etiology of the delayed gastric emptying cannot be determined. Despite this, several risk factors have been found in this subgroup of patients that put the patient at an increased risk of developing gastroparesis, but the relationship is not strong enough to be considered as an etiology.

For example, 21% of the idiopathic cases are thought to be postinfectious. Epstein-Barr, Hawaii, Norwalk, and rotavirus are all associated with an increased risk of delayed emptying after the acute gastroenteritis and this could be related to autonomic neuropathy. Fortunately, most cases of viral gastroparesis resolve in 18 to 24 months.

Diabetes-related gastroparesis
Half of the diabetic population is expected to have gastroparesis. Due to **autonomic diabetic neuropathy**, abdominal symptoms are less common in this subgroup of gastroparesis patients.

The pathophysiology of diabetic gastroparesis is better understood if compared to the idiopathic form. In long-standing diabetes, patients develop **neuromyopathy**, which is the cause of gastroparesis in this group.

In addition to neuromyopathy, **oxidative injury, along with reduced insulin concentration** in diabetes, are responsible for the **loss of Cajal cells**. Cajal cells are responsible for the synthesis of **nitrous oxide NO neurotransmitter**, which relaxes the **fundus** and decreases the tone of the **pylorus**. Loss of Cajal cells in diabetes would result in an increased pyloric tone and, eventually, delayed gastric emptying. Additionally, **gastric slow waves** and **peristalsis** are both impaired in diabetic autonomic neuropathy.

**Postsurgical gastroparesis**


In some abdominal surgeries such as **fundoplication for gastroesophageal reflux disease** and **bariatric surgery for obesity**, there is a risk of **vagus nerve injury**. If injured, **gastric stasis** could develop, which, in turn, may lead to gastroparesis.

**Gastrectomy, esophageal and pancreatic surgeries** are also related to the development of gastroparesis. **Pancreatic cancer cryotherapy**, for example, has a high risk for the development of temporary gastroparesis as a complication, in up to 67% of the cases.
Other etiologies of gastroparesis

Tricyclic antidepressants and alpha-2 adrenergic agonists slow gastric motility and could result in gastroparesis.

Parkinson’s disease is associated with neuronal degeneration in the dorsal nucleus of the vagus nerve which could result in gastroparesis.

Multiple sclerosis has also been linked to the development of gastroparesis due to a different pathology that is linked to the involvement of the white matter in the vagus nerve.

Infiltrative diseases, such as scleroderma, can cause gastroparesis because of the infiltration into the autonomic nerves and smooth muscles tissue.

Clinical Presentation of Gastroparesis

Sometimes, it is a challenge to differentiate between gastroparesis and functional dyspepsia. In this section, we cover both the non-specific symptoms of gastroparesis and the more specific ones.

In gastroparesis, gastric motor dysfunction is usually severe enough to cause more striking symptoms than simple dyspepsia, along with weight loss. Unfortunately, not all patients with gastroparesis are found to have weight loss, again making it a less sensitive symptom.

Another important controversy related to gastroparesis is the relationship between the severity of the symptoms and the degree of the delayed emptying of the stomach which is inconsistent.

The general symptoms of gastroparesis include abdominal pain, nausea, vomiting and, if severe enough, the formation of food bezoar. Due to the poor relationship between the symptoms and gastroparesis, the doctor has to have a low threshold to order more specific tests to confirm the diagnosis in a high-risk patient.

Diagnostic Workup of Gastroparesis

Laboratory investigations are only helpful in the exclusion of other possible differential diagnoses, such as pancreatitis, but cannot confirm the diagnosis of gastroparesis.

The first diagnostic test should be an esophagogastroduodenoscopy to exclude possible mechanical obstruction as the cause of the delayed gastric emptying. If the endoscopy did not reveal any structural or mechanical cause for the patient’s symptoms, further studies of the rate of gastric emptying are needed.

Gastric-emptying scintigraphy

Gastric-emptying scintigraphy (GES) is currently considered the gold standard for the diagnosis of gastroparesis. The patient is instructed to eat a radiolabeled meal and then repeated images of the stomach, along with a calculation of the remaining amount of the radiolabeled isotope, is carried out.

The American Neurogastroenterology and Motility Society has recently published diagnostic criteria for gastroparesis: If the patient has more than 90% retention of the radiolabeled material by 1 hour, > 60% by 2 hours and > 10% by 4 hours, he or she is
said to have delayed gastric emptying and possibly gastroparesis with high certainty.

The patient is instructed to avoid tobacco smoking, tricyclic antidepressants, adrenergic agents, promotility medications, and to make good control of hyperglycemia, if diabetic, before attempting to do the test, as all of these have been reported to impact the results.

Wireless capsule motility

The SmartPhill Corporation recently introduced a new wireless capsule that is indigestible and can provide a safer alternative than GES. The capsule measures pH, pressure, and temperature and can be used to investigate both gastroparesis and constipation.

In gastroparesis, the capsule determines the time it took to pass the stomach by noticing the sudden change in the pH, which demarcates the difference between the acidic and alkaline secretions of the stomach and pancreas in the duodenum, respectively. Usually, patients who are diagnosed to have gastroparesis with this method also have more than 90% retention by one hour if GES was performed.

Antroduodenal Manometry

This investigation is usually done during fasting to assess the migrating motor complex (MMC), which helps in differentiating between neuropathic and myopathy gastroparesis.

Antroduodenal manometry, as the name implies, works by measuring the intraluminal pressure in the antrum, pylorus and duodenal areas. Monitoring for 5 to 8 hours is usually needed. In myopathic disease, patients have low amplitude antral MMCs while, in diabetic neuropathy, the amplitude is normal but there is poor correlation between the three regions; the antrum, pylorus and duodenal.

Treatment Options for Gastroparesis

Once the diagnosis of gastroparesis is confirmed, the management usually involves dietary modifications, medication and, in more severe cases, possibly endoscopic surgery.

Dietary modifications for gastroparesis

The first step in the management of gastroparesis is to switch to a diet with smaller, more frequent meals with low-fat content and more liquid content. Nausea, vomiting, bloating and, to a lesser extent abdominal pain, all improved after the introduction of a small-particle diet in diabetic gastroparesis. Unfortunately, such studies
only provided short-term outcome results and long-term follow-up studies are needed.

Promotility agents

Promotility agents such as **TZP-102**, a **Ghrelin agonist**, are promising in the symptomatic relief of gastroparesis. Despite a significant decrease in the symptoms severity, researchers did not find any improvement in the rate of gastric emptying.

Despite this success, Ghrelin agonists are still in clinical trials and more traditional **prokinetic agents** such as **erythromycin** are usually used as first-line therapy. **Metoclopramide nasal spray or tablets** show good efficacy for symptomatic relief of gastroparesis but, again, this was not associated with an improvement in the gastric emptying rate.

Endoscopic intervention and surgery for gastroparesis

Surgery should be the last resort and only for severe and medically refractory cases of gastroparesis. **Near-total gastrectomy** has been evaluated as a possible last resort for medically refractory gastroparesis with good results in terms of semiology.

The study had a limitation as it did not show the rate of gastric emptying before the surgery, and the cohort has undergone several abdominal surgeries before for gastroesophageal reflux disease and pyloromyotomies.

More recently, **endoscopic pyloromyotomy** was introduced as an option for gastroparesis. The procedure is similar to peroral endoscopic myotomy for **achalasia** and was found to provide a significant improvement in gastroparesis-related symptoms. Larger, well-controlled clinical trials are still warranted to provide more evidence about the efficacy of this procedure.

Conclusion

While gastroparesis is common in certain populations such as patients with diabetes, the majority of the cases are of unknown causes. The main hallmark of gastroparesis is delayed gastric emptying which can be assessed by GES, a wireless capsule motility test or antroduodenal manometry.

Once the diagnosis is confirmed, the patients are instructed to follow a **small-particle diet with more liquids**. If not enough, **promotility agents** such as erythromycin and **antiemetics**, such as metoclopramide, are prescribed. Novel treatments such as **Ghrelin agonists** are promising for symptomatic relief. Finally, **surgery** should be a last resort in gastroparesis and long-term follow-up, well-controlled clinical trials are still needed.

References


Legal Note: Unless otherwise stated, all rights reserved by Lecturio GmbH. For further legal regulations see our [legal information page](#).